PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Harger, A. ; Stemmer, K. ; Tschöp, M.H. ; Müller, T.D.

Incretin-based co- and tri-agonists Innovative polypharmacology for the treatment of obesity and diabetes.

Incretin-based co- and tri-agonists: Innovative polypharmacology for the treatment of obesity and diabetes.

Internist 60, 895-902 (2019)
Postprint DOI PMC
Open Access Green
Background The worldwide rise in overweight and obesity is paralleled by an increasing prevalence of type-2 diabetes. Apart from bariatric surgery, treatment options to decrease body weight are often underwhelming. Innovative pharmacological options are required to cope with the global "diabesity" pandemic. Objectives Particular novel pharmacological approaches are discussed, with a special focus on polyagonist-based pharmacotherapies. Materials and methods Articles on co- and tri-agonists for the treatment of obesity and diabetes are presented and discussed. Results Unimolecular peptides have been developed for the treatment of obesity and type-2 diabetes. These peptides activate the receptors of multiple hormones and bundle their positive effects in one single molecule. In preclinical studies, polyagonists targeting the receptors for glucagon-like peptide-1 (GLP-1), glucagon, or glucose-dependent insulinotropic peptide (GIP) were promising to reduce body weight and blood glucose. GLP-1-mediated delivery of the nuclear hormones estrogen or dexamethasone also yielded beneficial effects in preclinical studies of obesity. Conclusions Polyagonists represent an innovative strategy for the development of novel pharmacotherapies to treat obesity and diabetes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
0.427
0.162
3
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Overweight ; Blood Glucose ; Glucagon-like Peptide 1 ; Glucose-dependent Insulinotropic Peptide ; Weight Loss; Glucagon Receptor Antagonist; Gastric-inhibitory Polypeptide; Type-2; Pharmacology; Pharmacodynamics; Pharmacokinetics; Ly2409021; Glucose; Biology; Safety
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 0020-9554
e-ISSN 1432-1289
Zeitschrift Internist, Der
Quellenangaben Band: 60, Heft: 9, Seiten: 895-902 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Berlin ; Heidelberg
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-502200-001
DOI 10.1007/s00108-019-0649-9
WOS ID WOS:000483776400003
Scopus ID 85069663237
PubMed ID 31346639
Erfassungsdatum 2019-08-02
[➜Korrektur melden]